you are here: HomeNewsBiocon
biocon
Jump to
1517 Results Found
  • COVID-19 | Biocon may apply for full marketing authorisation of itolizumab: Report Jul 26, 2021 12:38 PM IST

    COVID-19 | Biocon may apply for full marketing authorisation of itolizumab: Report

    Sold under the brand name Alzumab, itolizumab has been used in treatment of psoriasis treatment since 2013.

  • Biocon Consolidated June 2021 Net Sales at Rs 1,760.60 crore, up 5.34% Y-o-Y Jul 26, 2021 09:33 AM IST

    Biocon Consolidated June 2021 Net Sales at Rs 1,760.60 crore, up 5.34% Y-o-Y

  • Biocon Consolidated June 2021 Net Sales at Rs 1,760.60 crore, up 5.34% Y-o-Y Jul 23, 2021 10:52 AM IST

    Biocon Consolidated June 2021 Net Sales at Rs 1,760.60 crore, up 5.34% Y-o-Y

  • Biocon Standalone June 2021 Net Sales at Rs 382.70 crore, down 26.5% Y-o-Y Jul 23, 2021 10:50 AM IST

    Biocon Standalone June 2021 Net Sales at Rs 382.70 crore, down 26.5% Y-o-Y

  • Has SEBI erred in the Biocon insider trading case? Jul 13, 2021 10:55 AM IST

    Has SEBI erred in the Biocon insider trading case?

    Insider trading cases are hard to prove but regulators don’t stop trying to stamp out this menace. In Biocon’s case, Sebi’s orders raise vital questions on their soundness.

  • Biocon Q1 PAT seen up 21% YoY to Rs 180.7 cr: ICICI Direct Jul 12, 2021 07:35 PM IST

    Biocon Q1 PAT seen up 21% YoY to Rs 180.7 cr: ICICI Direct

    Net Sales are expected to increase by 13.4 percent Y-o-Y (up 3.1 percent Q-o-Q) to Rs 1,895.3 crore, according to ICICI Direct.

  • Sebi needs to act rationally in insider trading judgements: Kiran Mazumdar-Shaw Jul 09, 2021 09:08 PM IST

    Sebi needs to act rationally in insider trading judgements: Kiran Mazumdar-Shaw

    Mazumdar-Shaw's tweet came after Sebi barred Allegro Capital and one of its senior executives from the securities market for one year in a case related to alleged insider trading activities in the shares of Biocon.

  • Biocon shares underperform pharma index in a year; global brokerage retains sell Jul 06, 2021 01:38 PM IST

    Biocon shares underperform pharma index in a year; global brokerage retains sell

    Global research firm CLSA has maintained sell on the stock with target at Rs 260 per share. It is of the view that cash flow remained negative for an eighth consecutive year in FY21 with operating cash flow falling 24 percent YoY and capex intensity remaining high.

  • Insider trading case: SEBI bars Biocon's official from securities market for 3 months, levies fine Jul 01, 2021 11:39 AM IST

    Insider trading case: SEBI bars Biocon's official from securities market for 3 months, levies fine

    Biocon had announced information relating to its collaboration with Sandoz and the period of unpublished price sensitive information (UPSI) was from December 20, 2017 to January 18, 2018, The Securities and Exchange Board of India (Sebi) noted in an order passed late on Wednesday.

  • COVID-19 has created an 'ecosystem' of innovation in India: Kiran Mazumdar-Shaw Jun 15, 2021 12:03 PM IST

    COVID-19 has created an 'ecosystem' of innovation in India: Kiran Mazumdar-Shaw

    Kiran Mazumdar-Shaw, 68, is one of the key speakers at the 15th edition of the annual virtual summit on June 22 hosted by the USA India Chambers of Commerce.

  • Hold Biocon: target of Rs 400: ICICI Direct May 25, 2021 03:05 PM IST

    Hold Biocon: target of Rs 400: ICICI Direct

    ICICI Direct recommended hold rating on Biocon with a target price of Rs 400 in its research report dated April 29, 2021.

  • Biocon chief Kiran Mazumdar-Shaw compares COVID vaccination situation in India to arranged marriage May 15, 2021 06:09 PM IST

    Biocon chief Kiran Mazumdar-Shaw compares COVID vaccination situation in India to arranged marriage

    Earlier this week, Mazumdar-Shaw had expressed concern over shortage of COVID-19 vaccines and sought better transparency from the government regarding their availability so that citizens could patiently wait for their turn.

  • Remdesivir supply issues might ease by third week of May: Biocon's Kiran Mazumdar-Shaw May 03, 2021 02:46 PM IST

    Remdesivir supply issues might ease by third week of May: Biocon's Kiran Mazumdar-Shaw

    The sharp surge in COVID-19 cases across has created a massive demand and consequent shortage of medical oxygen and essential drugs.

  • Laurus Labs: Diversification to speed up in FY23; add on declines May 03, 2021 11:06 AM IST

    Laurus Labs: Diversification to speed up in FY23; add on declines

    There is a perceptible change in the Laurus Labs' management commentary in the last 18 months that points to growth sustenance for the medium term

  • Biocon Consolidated March 2021 Net Sales at Rs 1,838.70 crore, up 16.3% Y-o-Y Apr 29, 2021 12:03 PM IST

    Biocon Consolidated March 2021 Net Sales at Rs 1,838.70 crore, up 16.3% Y-o-Y

  • Biocon Standalone March 2021 Net Sales at Rs 491.60 crore, up 1.91% Y-o-Y Apr 29, 2021 11:24 AM IST

    Biocon Standalone March 2021 Net Sales at Rs 491.60 crore, up 1.91% Y-o-Y

  • We will have an abundant supply of Remdesivir by the second week of May: Biocon chief Kiran Mazumdar Shaw Apr 19, 2021 12:23 PM IST

    We will have an abundant supply of Remdesivir by the second week of May: Biocon chief Kiran Mazumdar Shaw

    Biocon Executive Chairperson Kiran Mazumdar Shaw says scarcity of critical anti-COVID-19 drugs Remdesivir and Itolizumab will end in 4-6 weeks as suppliers like her own company ramp up output that fell when the pandemic was receding. She said market pricing of vaccines is a must for the much-needed acceleration in inoculation.

  • Goldman Sachs Private Equity emerges frontrunner to acquire ChrysCap stake in GVK Biosciences Apr 18, 2021 06:26 PM IST

    Goldman Sachs Private Equity emerges frontrunner to acquire ChrysCap stake in GVK Biosciences

    The CRAMs ( contract research and manufacturing services) segment is fetching rich valuations globally and back home, the segment has seen minority stake sale deals like True North-Anthem Biosciences & TPG-Sai Lifesciences.

  • Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan Apr 12, 2021 08:40 PM IST

    Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan

    Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.

  • Biocon's arm gets GMP compliance certificate from UK's health regulator MHRA for Bengaluru facility Apr 12, 2021 10:58 AM IST

    Biocon's arm gets GMP compliance certificate from UK's health regulator MHRA for Bengaluru facility

    "Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru," Biocon said in a regulatory filing.

  • What ‘second wave’ means for investors in Indian pharma Apr 12, 2021 10:25 AM IST

    What ‘second wave’ means for investors in Indian pharma

    Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma

  • Biocon Biologics, Viatris receive EC approval for biosimilar insulin aspart Kixelle Feb 12, 2021 11:13 AM IST

    Biocon Biologics, Viatris receive EC approval for biosimilar insulin aspart Kixelle

    This follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, a Biocon statement said on Friday.

  • Neutral Biocon; target of Rs 385: Motilal Oswal Feb 02, 2021 09:11 PM IST

    Neutral Biocon; target of Rs 385: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 385 in its research report dated January 22, 2021.

  • Buy Biocon; target of Rs 470: Sharekhan Feb 01, 2021 06:36 PM IST

    Buy Biocon; target of Rs 470: Sharekhan

    Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated January 22, 2021.

  • Hold Biocon; target of Rs 450: ICICI Direct Jan 28, 2021 02:58 PM IST

    Hold Biocon; target of Rs 450: ICICI Direct

    ICICI Direct recommended hold rating on Biocon with a target price of Rs 450 in its research report dated January 22, 2021.

Sections
ISO 27001 - BSI Assurance Mark